Target intelligence / Profile preview

Alpha-bungarotoxin (α-BTX) (α-BTX)

Target
α-BTX
Molecular classification
Three-finger toxin (3FTx) family, Snake venom neurotoxin, Postsynaptic neurotoxin
01

Overview

Alpha-bungarotoxin and related low molecular weight neurotoxins from the kraits Bungarus multicinctus and Bungarus candidus are potent members of the three-finger toxin (3FTx) family (UniProt P01378, P01377). These toxins function as highly specific and nearly irreversible antagonists of the nicotinic acetylcholine receptor (nAChR) at the postsynaptic membrane of the neuromuscular junction (Nirthanan & Gwee, 2004). By blocking the binding of the neurotransmitter acetylcholine, these toxins prevent muscle contraction, leading to progressive flaccid paralysis and potentially fatal respiratory failure in envenomed victims (WHO, 2016). While these neurotoxins are not therapeutic targets for treating human diseases, they are the primary pathological agents targeted for neutralization by antivenom therapy (StatPearls, 2023). In pharmacological research, alpha-bungarotoxin has served as a gold-standard tool for labeling and studying the distribution of nAChRs in the nervous system. Clinical management of envenomation relies on the timely administration of specific antivenoms, which contain antibodies that bind and sequester the toxins in the circulation (WHO, 2016). The high affinity of these toxins for their receptor makes them both a significant clinical challenge and a powerful tool in molecular biology.

Other names
α-Bungarotoxinα-BTXMany-banded krait neurotoxinMalayan krait neurotoxinThree-finger toxin3FTxPostsynaptic neurotoxin type I
02

Mechanism of action

Antivenoms neutralize the toxins by binding to their active epitopes, preventing the toxins from interacting with the nicotinic acetylcholine receptors (nAChR) at the neuromuscular junction (WHO, 2016; StatPearls, 2023).

03

Biological functions

Nicotinic acetylcholine receptor antagonismInhibition of neuromuscular transmission
04

Disease associations

Snakebite envenomationNeuromuscular paralysisAcute respiratory failure
05

Safety considerations

Anaphylaxis to antivenomSerum sickness (Type III hypersensitivity)Rapid progression of irreversible paralysis if treatment is delayed
06

Interacting drugs

Bungarus multicinctus antivenom

2 more in the full profile.

07

Biomarkers

Serum venom antigen levels (ELISA)Clinical neurotoxicity scores (e.g., degree of ptosis)Respiratory capacity (vital capacity)

Beyond the preview

Go deeper on Alpha-bungarotoxin (α-BTX) (α-BTX).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Alpha-bungarotoxin (α-BTX) (α-BTX).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call